Compare Ascendis Pharma A/S (ASND) vs LYFT Inc (LYFT) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Ascendis Pharma A/S vs LYFT Inc — how do they compare? Ascendis Pharma A/S trades at $270.99 (market cap $17.74B), while LYFT Inc trades at $15.61 (market cap $5.93B). The key difference: Ascendis Pharma A/S is far larger — about 3× LYFT Inc's market cap, and Ascendis Pharma A/S is trading nearer its 52-week high, LYFT Inc nearer its low. Which is the better fit depends on your goals.
| ASND | LYFT | |
|---|---|---|
Market Cap | $17.74B | $5.93B |
Sector | Health | Industrials |
52-Week High | $277.18 | $24.57 |
52-Week Low | $163.32 | $12.65 |
Enterprise Value | $18.11B | $5.46B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
Lyft trades at $15.61, down 0.83% on the day, with a bullish technical signal from moving averages and key indicators like ADX. The company shows strong profitability with a net income margin of 43.82% and robust cash flow of $891M in 2025. Recent news highlights expansion into Europe and autonomous vehicle partnerships, while analyst consensus is mixed with a $18.25 price target.
Lyft presents an attractive valuation with a P/E of 2.28 and P/S of 0.99, but faces risks from competitive pressures and inconsistent earnings beats. The stock's upside potential hinges on execution of growth initiatives, though regulatory concerns and market volatility remain key watchpoints for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About LYFT Inc
Lyft is the second-largest ride-sharing service provider in the U.S., connecting riders and drivers over the Lyft app. Lyft recently entered the Canadian market in an effort to expand its market outside the U.S. Incorporated in 2013, Lyft offers a variety of rides via private vehicles, including traditional private rides, shared rides, and luxury ones. Besides ride-share, Lyft also has entered the bike- and scooter-share market to bring multimodal transportation options to users.
Read more on LYFT →
